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The reported prevalence of neuropathic pain ranges from 6.9% to 10%; however the only Canadian study reported 17.9%. The
objective of this study was to describe the epidemiology of neuropathic pain in Canada. A cross-sectional survey was conducted
in a random sample of Canadian adults. The response rate was 21.1% (1504/7134). Likely or possible neuropathic pain was defined
using a neuropathic pain-related diagnosis and a positive outcome on the Self-Report Leeds Assessment of Neuropathic Symptoms
and Signs pain scale (S-LANSS) or the Douleur Neuropathique 4 (DN4) Questions. The prevalence of likely neuropathic pain was
1.9% (S-LANSS) and 3.4% (DN4) and that of possible neuropathic pain was 5.8% (S-LANSS) and 8.1% (DN4). Neuropathic pain was
highest in economically disadvantaged males. There is a significant burden of neuropathic pain in Canada. The low response rate
and a slightly older and less educated sample than the Canadian population may have led to an overestimate of neuropathic pain.
Population prevalence varies by screening tool used, indicating more work is needed to develop reliable measures. Population level
screening targeted towards high risk groups should improve the sensitivity and specificity of screening, while clinical examination
of those with positive screening results will further refine the estimate of prevalence.
1. Introduction
Neuropathic pain was recently redefined by the International
Association for the Study of Pain as “pain caused by a lesion
or disease of the somatosensory nervous system” [1] and
graded as “possible,” “probable,” or “definite,” depending on
the extent and results of neurological assessment [2, 3]. Early
estimates of the prevalence of neuropathic pain based on
physical examination in clinic populations ranged from 1% to
3% [4–7]. In the general population, previous estimates based
on self-report ranged from 6.5% to 17.9% [8–13]. A recent
systematic review of epidemiological studies on neuropathic
pain suggests that the prevalence likely lies between 6.9%
and 10% [14]. Neuropathic pain is a clinical entity [1], the
diagnosis of which is based primarily on history and physical
examination [15–19] and the exclusion of other possible
diagnoses or types of pain. The impracticality of conducting
clinical examinations in large population studies and the lack
of a “gold standard,” in addition to the variety of screening
tools and the way in which they are administered, contribute
to the heterogeneity of estimates of neuropathic pain in the
general population [14].
Neuropathic pain is often experienced in parts of the body
which otherwise appear normal. It is characterized by features
such as numbness, paresthesia, and allodynia [20], and it
is generally nonresponsive to standard analgesics to treat
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chronic pain [21]. It is also associated with longstanding and
severe pain [22] andwith a burden of disease similar to that of
other chronic conditions, includingmental health conditions
[23]. A multitude of conditions can cause neuropathic pain,
including lumbar and cervical radiculopathy, painful diabetic
neuropathy, HIV-related neuropathy and cancer-related neu-
ropathic pain syndromes [17, 24–27]. Certain groups within
the general population have been identified as having a higher
burden of neuropathic pain, including women [8, 10–12, 28],
older people [8, 10, 11, 28], those with less formal education
[10, 11], manual workers or farmers [8], those unable to work
[11], those living in rural residences [8], non-home owners
[11], and those perceiving themselves as being economically
disadvantaged [12]. There is inconsistent evidence on the
relationship between marital status and neuropathic pain
[8, 10, 11]. There is also insufficient evidence to suggest a
regional pattern of neuropathic pain prevalence.Most studies
have been conducted in Europe and the United Kingdom
where rates are lower compared to the few reports from
other parts of the world. In the Americas, 9.8% has been
reported with clinical examination and 12.4% using self-
report in Olmsted County, Minnesota, USA [29], and 10% in
Brazil [13]. The only Canadian study, conducted in Alberta,
reported a prevalence of 17.9%, considerably higher compared
to reports in other parts of the world [12].
The purpose of this study was to describe the epidemiol-
ogy of neuropathic pain in a pan-Canadian community sam-
ple. The specific objectives were to estimate the prevalence
and characteristics of likely or possible neuropathic pain and
to identify subgroupswith a high burden of neuropathic pain.
2. Methods
This cross-sectional study was reviewed for ethical com-
pliance and received approval from the Queen’s Univer-
sity Health Sciences Research Ethics Board (HSREB). The
requirement for written informed consent was waived by
the HSREB.The polling company, SM Research (http://www
.smres.com/), used the national telephone directory to pro-
vide a random sample of 8000 households in the ten Cana-
dian provinces.Thismethodprovides each householdwith an
equal opportunity to be included in the sample. At the time of
sampling, approximately 80% of Canadian households were
listed in the directory with 20% not covered because they
did not have a landline or were unlisted. After the survey
was complete, SM Research provided weights so the sample
could be age- and sex-matched to the 2011 Canadian Census
data [30]. Based on published prevalence estimates, it was
established that a sample size of 4000 would result in 95%
confidence intervals (CI) ranging from 0.6% for a prevalence
of 3.3% to 1.2% for a prevalence of 17.9% [31].
2.1. Participants. Potential participants were sent a bilingual
(French and English) cover letter explaining the study. Due
to the restrictive cost of postage, a unilingual paper ques-
tionnaire based on most likely language (as identified by
polling company SMResearch) was included.This resulted in
French questionnaires being sent to all potential participants
residing in the province of Quebec and those identified
outside of Quebec as likely being French by the polling
company (SM Research). Participants were encouraged to
contact the research team if they preferred a questionnaire in
the alternate language. In addition, they were provided with a
link to an online version of the questionnaire in both official
languages. Participants completing online questionnaires
were required to enter their unique identifying number to
allow for tracking of responses and to prevent the inclusion
of duplicate (paper and online) responses. By completing the
questionnaire, consent was implied.The online questionnaire
was created using Student Voice (http://www.studentvoice
.com/). Each envelope contained a stamped, self-addressed
return envelope. The first mail out occurred in November
2011. Response time was delayed due to a postal disruption
just before the initial mail out; therefore a follow-up to
nonresponders was delayed until May 2012, when fewer than
20 questionnaires per week were being returned.
2.2. Case Identification and Measurement Tools. Individuals
with chronic pain were identified by affirmative answers to
two screening questions: (i) Are you currently troubled by
pain or discomfort, either all of the time or on and off? and
(ii) Have you had this pain or discomfort for more than
3 months? These case identification questions are based on
the International Association for the Study of Pain definition
of chronic pain [32] and have been validated and used in
previous studies of chronic pain [11, 33, 34]. Participants with
positive responses to both questionswere asked the following:
How often are you bothered by this pain or discomfort (all
the time, daily (but not the entire day), nearly daily, on
and off)? The frequency categories were based on reports
from previous studies [11, 12]. Participants were asked to
identify the location of the most troublesome pain based on
a numbered body manikin which included back; neck or
shoulder; head, face, or teeth; stomach or abdomen; arms or
hands; chest; hips; and legs or feet [35] and to identify all
body sites at which they experienced pain. They were also
asked if they had been diagnosed with any of the following
common causes of pain: a surgical operationmore than three
months ago, back problems (such as a slipped disc, back
surgery, or sciatica), diabetes, an accident that damaged a
nerve, amputation of a limb, fibromyalgia, leg ulcers, shingles,
cancer, chronic widespread pain, migraine, arthritis, and
vulvodynia.
The Self-Report Leeds Assessment of Neuropathic Symp-
toms and Signs (S-LANSS) pain scale and the Douleur
Neuropathique 4 (DN4) Questions, both of which have been
validated in clinical populations with neuropathic pain, were
used to screen for chronic pain with neuropathic character-
istics [36, 37].The S-LANSS consists of 5 symptom items and
2 self-examination items, with responses weighted to provide
a score ranging from 0 to 24. A score of ≥12 is suggestive of
pain with neuropathic characteristics [36]. The S-LANSS has
a sensitivity of 74% and a specificity of 76% when compared
to clinical examination [36]. The self-report version of the
DN4 consists of 7 items related to symptoms. Participants
are asked for a yes/no response to questions about quality
of pain (burning, painful cold, and electric shocks) and
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its association with abnormal sensations (tingling, pins and
needles, numbness, and itching). The summary score ranged
from 0 to 7 with a score of ≥3 out of 7 being suggestive of
chronic pain with neuropathic characteristics [37]. In order
to be classified as neuropathic pain, an individual also had to
report a likely (accident with nerve damage, amputation, and
shingles) or possible (surgery more than 3 months ago, back
problem, diabetes, and cancer) neuropathic pain diagnosis
(the full list is available upon request).This self-report version
of the DN4 has a sensitivity of 78% and a specificity of 81%
[38].
Severity of neuropathic pain was measured using the
Neuropathic Pain Scale (NPS), a series of 11-item numerical
rating scales that address specific features of the pain experi-
ence (intensity, sharpness, hotness, dullness, coldness, sensi-
tivity, and itch) and items measuring unpleasantness, timing,
and surface and deep pain [39]. Median and interquartile
range (IQR) were calculated for each item. Help seeking
behavior was assessed using the Level of Expressed Need
(LEN) questionnaire [40]. The LEN asks about the seeking
of treatment and use of painkillers. The 4 questions of
the LEN are summed to create a score ranging from 0
to 4, with 0 reflecting no treatment or painkillers and 4
representing maximum need (frequent use of painkillers
and recent treatment sought). Participants were also asked,
“What treatments or medications are you receiving for your
pain?”
Participants were asked to report any diagnosed chronic
health conditions including asthma; anxiety disorder (e.g.,
phobia, obsessive-compulsive disorder, or panic disorder);
bowel disorder (e.g., Crohn’s disease, ulcerative colitis, irri-
table bowel syndrome, or bowel incontinence); chronic
bronchitis, emphysema, or chronic obstructive pulmonary
disease; chronic fatigue syndrome; diabetes; heart disease
(e.g., heart attack, congestive heart failure); hypertension or
high blood pressure; mood disorder (e.g., depression, bipolar
disorder, mania, or dysthymia); multiple chemical sensitivi-
ties; intestinal or stomach ulcers; stroke; and urinary inconti-
nence. Sociodemographic characteristics captured included
age, gender, smoking history, marital status, employment
status, educational attainment, income, and home ownership.
Age was categorized into approximate quartiles to match
categories used in the Canadian Census data and thereby
allow for extrapolation to the Canadian population. Age
was also categorized by a median split for the purpose
of the multivariable analysis. Income was categorized into
approximate tertiles, again to allow for comparisons with
Census data.
2.3. Data Analysis. Data quality checks were conducted using
established methodology before merging datasets [41]. Every
tenth questionnaire was checked and if an entry error was
found every survey was checked until ten consecutive error-
free surveys were reviewed [41]. Once the quality check
was completed, online survey data were downloaded into a
Microsoft Excel file and merged with the manually entered
data which were also inMicrosoft Excel. Descriptive statistics
were used to summarize characteristics of the study sample.
Prevalence estimates were age- and sex-weighted to the 2011
Canadian Census data [30]. For logistic regression and deci-
sion tree analyses, weights were scaled down (weight/5000)
to avoid excessively narrow estimates of precision. The
prevalence of chronic pain with neuropathic characteristics
was calculated in three ways: as the percentage with a positive
score on the (i) S-LANSS (≥12), (ii) the DN4 (≥3), and
(iii) on both tools. The prevalence of neuropathic pain was
calculated as the percent with chronic pain with neuropathic
characteristics and with a likely or possible neuropathic pain
diagnosis. The clinical and pain characteristics of individuals
with neuropathic pain were described using percentages
and measures of central tendency. Unadjusted and adjusted
logistic regression analyses were conducted to examine the
relationship between sociodemographic characteristics and
neuropathic pain. Decision tree analysis was conducted to
identify the subgroups reporting the highest percent of indi-
viduals with neuropathic pain. Variables were dichotomized
to ensure adequate cell frequencies. The percentage of the
total population within each subgroup and the percentage of
individuals with neuropathic pain within each subgroup are
reported. Risk estimates (standard error) were calculated as a
measure of the tree’s predictive accuracy. The risk estimate is
the proportion of cases incorrectly classified after adjustment
for prior probabilities and misclassification costs (SPSS
online help Decision Tree Option). The percent of missing
items was calculated for the S-LANSS, DN4, and NPS. To
minimize the effect of missing data on the screening tools,
missing values were assigned a “0.” This would have resulted
in a conservative total score for the S-LANSS and DN4.
Analysis was conducted using IBM SPSS version 22 [42].
3. Results
Of the 8,000 questionnaires, 866 (10.8%) were returned
due to wrong address, 4,539 (56.8%) were not returned,
2,595 (32.4%) were returned, and 1,509 (18.9%) were at least
partially completed (Figure 1). A postal strike delayedmailing
of the questionnaires and may have affected the delivery
and return of questionnaires even after the postal strike was
over. The corrected response rate based on the proportion
of questionnaires sent to the correct address and with the
pain screening questions completed was 21.1% (1504/7134).
Ninety-three percent (1395/1504 = 92.8%) of respondents
completed paper questionnaires and 7.2% (109/1504) com-
pleted online questionnaires. The percent of missing data
ranged from 2.0% to 5.7% on the S-LANSS, 9.2% to 15.0%
on the DN4, and 3.2% to 5.0% on the NPS. The percent of
missing responses on potentially sensitive questions was also
examined (e.g., household income (8.5% missing) and home
ownership status (2.9% missing)). Respondents completing
paper questionnaires were significantly older (mean = 58 SD
= 14 versus mean = 50 SD = 13, 𝑡-test = 5.5, and 𝑝 < 0.01),
reported lower household income, were retired, and had less
education than those completing online questionnaires.
The prevalence of likely neuropathic pain was 1.9%
(margin of error (ME) = 0.7, sample 𝑛 = 33, population
𝑁 = 504,137) on the S-LANSS and 3.4% (ME = 0.9, 𝑛 =
48, 𝑁 = 894,618) on the DN4. The prevalence of possible
neuropathic pain was 5.8% (ME = 1.1, 𝑛 = 90,𝑁 = 1,526,214)
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Survey mailed to 8000 potential respondents
November 2011
866 returned to sender
4,539 surveys missing
1,509 completed screening question 1
553 with no pain, 956 with pain
956 with pain
162 did not provide duration)
1,086 refused
184 with chronic pain
with neuropathic
characteristics
235 with chronic pain
with neuropathic
characteristics
123 with neuropathic 166 with neuropathic
2,595 surveys returned
pain∗pain∗
741 with chronic pain (>3 months)
215 with acute pain (53 reported pain ≤3 months +
(DN4 ≥ 3)
(DN4 ≥ 3)(S-LANSS ≥ 12)
(S-LANSS ≥ 12)
Figure 1: Flowchart of sample participants. Question 1: Are you
currently troubled by pain or discomfort, either all the time or
on and off? ∗Diagnosed with a likely or possible neuropathic pain
condition and positive on the screening tool.
on the S-LANSS and 8.1% (ME = 1.3, 𝑛 = 118,𝑁 = 2,132,903)
on the DN4. The remaining results focus on the combined
prevalence of likely or possible neuropathic pain.
Table 1 includes the sociodemographic and comorbidity
characteristics for the sample (𝑛 = 1504) and the age-
and sex-weighted population of Canadian adults (𝑁 =
26,423,076). The largest proportions of participants were
from Ontario (38.3%) and Quebec (24.0%), which is consis-
tent with the distribution by province captured in the 2011
Canadian Census (Table 1). Sociodemographic and clinical
characteristics stratified by likely or possible neuropathic pain
using the S-LANSS and the DN4 are also reported in Table 1.
The overall prevalence of neuropathic pain was higher on
the DN4 than on the S-LANSS and this pattern persisted
formost of the sociodemographic and clinical characteristics.
However, in some cases the prevalence wasmuch higher than
would be expected on the DN4 compared to the S-LANSS
(e.g., male 13.6% versus 6.5%, 18–39-year-olds 9.6% versus
3.5%, stroke 30.3% versus 13.5%, anxiety 36.1% versus 16%,
and mood disorder 28.9% versus 16.8%).
Of the total population represented by this sample, 4.9%
reported having had an accidentwith nerve damage (Table 2).
Of the 4.9%, 31.4% had a positive screen for neuropathic
pain characteristics on the S-LANSS and 51.6% on the DN4.
The prevalence of neuropathic pain by all sites and the most
troublesome site is reported in Table 3. The highest preva-
lence of neuropathic characteristics was reported in lower
extremities (S-LANSS 73.1%, DN4 78.4%), back/buttocks
(S-LANSS 68.9%, DN4 73.0%), and upper extremities (S-
LANSS 64.7%, DN4 61.1%); however the most troublesome
site was the back/buttocks (S-LANSS 27.9%, DN4 32.6%).
Approximately half of the population with neuropathic pain
reported background pain all of the time with occasional
flare-ups some of the time (S-LANSS 51.7%, DN4 55.8%).The
median pain intensity of neuropathic pain was 6.0/10 (IQR
5.0–8.0) (S-LANSS) and 7.0/10 (5.0–8.0) (DN4). The highest
pain ratingswere described as sharp (both tools 7.0 (4.0–8.0)),
dull (both tools 5.0 (3.0–7.0)), and hot (S-LANSS 4.0 (2.0–
6.0), DN4 3.0 (1.0–5.0)). Deep pain intensity was rated as
a median of 7.0 (5.0–8.0) (both tools) and surface pain was
rated as 5.0 (3.0–7.0) (S-LANSS) and 4.0 (2.0–6.0) (DN4).
Over one-third of those with neuropathic pain reported the
maximum Level of Expressed Need; that is, treatment was
sought and painkillers were used frequently and recently (S-
LANSS 39.7%, DN4 40.3%). The most common forms of
treatment for pain were prescription opioid and/or prescrip-
tion anti-inflammatory medication (S-LANSS 27.1%, DN4
24.8%) or over the counter analgesics (S-LANSS 26.6%, DN4
23.7%).
The unadjusted and adjusted odds ratios (OR) and 95%
confidence intervals (CI) for sociodemographic characteris-
tics associated with neuropathic pain are reported in Table 4.
In the adjusted model, the factors significantly associated
with increased odds of neuropathic pain (S-LANSS) were
income (<$50,000 OR = 4.59, 95% CI 3.26–6.46; $50,000–
$99,999 OR 1.58, 95% CI 1.13–2.21; and ref ≥$100,000), being
unemployed (OR = 1.89, 95% CI 1.43–2.46, and ref = working
full- or part-time), and being a past smoker (OR = 1.86,
95% CI 1.47–2.35, and ref = never smoked). Being married
decreased the odds of neuropathic pain (OR = 0.56, 95%
CI 0.44–0.72). Similar findings existed for the DN4 analysis:
income (<$50,000 OR = 3.44, 95% CI 2.59–4.58; $50,000–
$99,999 OR 2.16, 95% CI 1.65–2.83; and ref ≥$100,000), being
unemployed (OR= 3.05, 95%CI 2.42–3.84, and ref = working
full- or part-time), and being a current smoker (OR = 2.39,
95% CI 1.88–3.05, and ref = never smoked). Being female
had increased odds for neuropathic pain in the S-LANSS
model (OR = 1.46, 95% CI 1.17–1.81) and decreased odds in
the DN4 model (OR = 0.60, 95% CI 0.50–0.72). Contrary
results were also found for age between the two outcomes.
Mode of survey (paper versus online) administration was
significant in bivariate analysis. It was not included in the
multivariable model due to the low number of individuals
who completed the online component (𝑛 = 109), which
would have affected the stability of the analysis, and due
to the potential for confounding because of its relationship
with both the independent factors (i.e., age, income) and the
outcome.
When all significant sociodemographic main effect terms
were included in the decision tree analysis, the highest
prevalence of neuropathic pain (S-LANSS) was found in
males who were unemployed with an income <$50,000
per year (32.5%, 𝑁 = 226,926) (Figure 2(a)). The lowest
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Total 
(100.0/7.7)
(69.4/4.6)
(40.1/2.0)
Male
(20.3/0.6)
Female
(19.6/3.5)
(29.5/8.2)
Never
(14.1/6.1)
Past or current
smoker
(15.4/10.1)
(30.4/14.7)
Employed or
retired
(23.5/11.5)
(17.3/8.7)
(6.1/19.3)
Unemployed
(6.9/25.5)
Female
(4.3/21.2)
(2.6/32.5)
population
old
old
smoked
old
old
18–49 years
18–49 years
50–93 years
50–93 years
Male∗
$50,000
$50,000
Income ≥
Income <
(a)
Total 
(100.0/11.5)
Employed or 
retired
(85.7/9.2)
Never
(46.3/5.8)
(35.1/4.2)
(11.2/10.8)
Past or current
smoker
(39.4/13.2)
(27.1/11.7)
(12.2/16.7)
Unemployed
(14.3/24.9)
Female
(8.9/13.4)
(4.6/8.8)
(4.3/18.4)
Male
(5.4/44.0)
Married or living
as married
(3.6/29.6)
(1.8/73.2)
population
smoked
$50,000
$50,000
$50,000
$50,000
$50,000
$50,000
Not married
Income ≥
Income ≥
Income ≥
Income <
Income <
Income <
(b)
Figure 2:Decision tree analysis-percent of population in each subgroup and the percentwith neuropathic painwithin the respective subgroup
(𝑁 = 26, 423, 339). (a) Probable or possible neuropathic pain condition and screening positive on the SLANSS (Self-Report Version of the
Leeds Assessment of Neuropathic Symptoms and Signs). Risk estimate (standard error) = 0.077 (.004). (b) Probable or possible neuropathic
pain condition and screening positive on the DN4 (Douleur Neuropathique 4). Risk estimate (standard error) = 0.106 (0.000). Numbers in
brackets represent % of total population and % with neuropathic pain within that subpopulation e.g., ∗Male (2.6/32.5) = 32.5% of males who
were unemployed with an annual income <$50,000 reported neuropathic pain and this represents 2.6% of the total population of Canada.
All findings have an adjusted 𝑝 value <0.001. Growing method was CHAID.
prevalence was found in males aged 18 to 49 years with an
income ≥$50,000 (0.6%, 𝑁 = 33,740). This represents a
relative risk of 54.2 (32.5/0.6) in males who were unemployed
with an income <$50,000 per year versus males aged 18 to
49 years with an income ≥$50,000. In the DN4 decision
tree analysis, the highest prevalence of neuropathic pain was
found in unmarried males who were unemployed (73.2%,
𝑁 = 344,881) (Figure 2(b)). The lowest prevalence was
found in individuals with an income≥$50.000who had never
smoked and were employed or retired (4.2%, 𝑁 = 389,816).
This represents a relative risk of 17.4 (73.2/4.2).
4. Discussion
This is the first study to use two validated screening tools
to report the prevalence of neuropathic pain in a general
population. The prevalence of likely or possible neuropathic
pain was 7.7% (S-LANSS) and 11.5% (DN4). Males were twice
as likely to report neuropathic pain using the DN4 compared
to the S-LANSS (13.6% vs. 6.5%). Less than 10% used
a combination of medication and nonmedication therapy.
Males who were economically disadvantaged had the highest
burden of neuropathic pain.
Chronic pain with neuropathic characteristics, that is,
based on the results of the screening tool alone, not taking
into account diagnosis, is lower in our study (11.8% S-LANSS,
16.1% DN4), compared to the one other Canadian study
(17.9% DN4) [12]. In the other Canadian study by Toth et
al., respondents were asked to complete the DN4 if they
reported “daily or near-daily pain” perhaps resulting in an
overestimate of neuropathic pain [12]. Our prevalence of
neuropathic pain (taking diagnosis into account) of 7.7% (S-
LANSS) is consistent with the prevalence of chronic painwith
neuropathic characteristics (not accounting for diagnosis)
reported in the UK (UK 8%) [11], but the DN4 based estimate
(11.5%) is higher compared to reports inGermany (6.5%) [10],
France (6.9%) [8], and Morocco (10.6%) [9].
Neuropathic painwas associatedwith low income, unem-
ployment, smoking, and being unmarried.Other studies have
reported similar findings [8, 11, 12]. Unique to this study is
the fact that males had a higher prevalence of neuropathic
pain than females (DN4). In addition, there was a high
burden in males who were economically disadvantaged.
This suggests potential deprivation-related factors, while the
high prevalence of back disorder diagnoses suggests certain
occupations involving manual labour that may increase the
risk for neuropathic pain.
Neuropathic pain was associated with hypertension, dia-
betes, bowel disorders, and mood disorders. The limited
quality and completeness of data on comorbidities have been
well documented [43]; however self-report of comorbidities
has been shown to be comparable to documentation in the
medical record [44, 45]. Several of our findings are consistent
with the literature. Hypertension and bowel disorders have
been associated with chronic pain conditions in other studies
[46–51]. Individuals with diabetes may experience diabetic
neuropathy, and this group is also thought to have a higher
prevalence of other neuropathic pain conditions due to a
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Table 2: Percent of respondents with pain-related diagnoses who were screened positive for neuropathic characteristics on the S-LANSS and
the DN4a.
Total Diagnosed with pain condition
Sample
(𝑛 = 1504)
𝑛 (%)
Population
(𝑁 = 26,423,076)
%
S-LANSS ≥ 12b
(𝑁 = 3,128,817)
%
DN4 ≥ 3b
(𝑁 = 4,264,722)
%
Likely neuropathic diagnosis
Accident with nerve damage 72 (4.8) 4.9 31.4 51.6
Shingles 32 (2.1) 1.6 29.0 48.0
Amputation 3 (0.2) 0.2 51.9 100
Possible neuropathic diagnosis
Back 297 (19.7) 19.2 19.6 32.3
Surgery 123 (8.2) 8.8 33.5 40.8
Diabetes 104 (6.9) 4.9 34.3 39.4
Cancer 31 (2.1) 1.5 37.1 36.6
Unlikely neuropathic diagnosis
Osteoarthritis 239 (15.9) 12.6 9.1 11.0
Arthritis—osteoarthritis or rheumatoid 114 (7.6) 7.0 25.9 17.3
Migraine 98 (6.5) 6.7 17.6 17.4
Rheumatoid arthritis 59 (3.9) 3.2 19.9 12.5
Chronic widespread pain 39 (2.6) 2.5 25.3 56.4
Fibromyalgia 35 (2.3) 1.9 37.5 50.6
Leg ulcers 6 (0.4) 0.3 0.0 0.0
Vulvodynia 4 (0.3) 0.2 0.0 67.6
aIndividuals could select more than 1 condition.
bThe percentage screening positive for possible neuropathic diagnosis excludes those with a concurrent likely neuropathic diagnosis.The percentage screening
positive for unlikely neuropathic diagnosis excludes those with a concurrent likely or possible neuropathic diagnosis. S-LANSS = Self-Report Leeds Assessment
of Neuropathic Symptoms and Signs; DN4 = Douleur Neuropathique 4.
“double crush” neuropathic susceptibility [52]. Finally, the
high correlation between chronic pain and mood disorders
has been documented [53].
Using the grading system for neuropathic pain [1, 3],
likely neuropathic pain was consistent with clinical preva-
lence [4–7], and likely and possible neuropathic pain was
consistent with population prevalence [14]. Related to this
is the limited sensitivity and specificity of existing screening
tools. A proportion of respondents who were positive for
chronic pain with neuropathic characteristics had a pain
condition that was unlikely neuropathic. Similar findings
have been reported with the DN4: fibromyalgia (93% Toth
et al. 2009 [12] versus 51% our study), migraine (36% versus
17%), osteoarthritis (11% versus 11%), and vulvodynia (60%
versus 68%) [12]. False positive results are partially related
to features (e.g., burning, shooting, and allodynia) common
to DN4 and S-LANSS not being completely exclusive to
neuropathic conditions. However, a higher proportion of
likely neuropathic conditions were positive on the screening
tools than were conditions that were unlikely neuropathic.
Strengths of this study include the use of two screening
tools and the inclusion of a neuropathic pain-related diag-
nosis to measure the prevalence. This permitted a gradation
of estimates ranging from chronic pain with neuropathic
characteristics to likely neuropathic pain. An additional
strength is the national scope of the study; inclusion of all
provinces in Canada; and the use of bilingual questionnaires.
Due to low response rates, territories were not included, nor
were questionnaires available in languages spoken by the First
Nations people of Canada, which likely contributed to the
lack of response in the territories. Nor have the current tools
been validated in these cultures or languages. A limitation
was provision of the initial questionnaire in the assumed
first language of the potential participant, as identified by
the polling company. This may have deterred individuals
who required a questionnaire in the other official language.
However, therewas nodifferential response by language given
that the ratio of French to English questionnaire completion
was reflective of language as reported on the Canadian
Census. A further strength was that random sampling was
used for selecting the study sample and weighting the final
sample to the age and sex of the population. With the
exception of being older and having lower income, the age-
and sex-weighted demographic characteristics of the study
sample were similar to the Canadian Census data.
A limitation of our study was the inability to validate the
presence of neuropathic pain through clinical examination.
We used the best available methodology for identifying
neuropathic pain in the community, which relies on a
combination of screening tools and relevant diagnosis [54].
However, if respondents incorrectly cited a neuropathic pain
diagnosis and if they were positive on a tool, we would have
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Table 3: Characteristics and management of neuropathic pain (sample weighted to general population).
Likely or possible NP (S-LANSS)a
(𝑁 = 2,030,351)
Likely or possible NP (DN4)b
(𝑁 = 3,027,521)
% %
All pain sitesc
Lower extremities 73.1 78.4
Back/buttocks 68.9 73.0
Upper extremities 64.7 61.1
Neck 33.6 22.9
Chest/abdomen 31.1 24.2
Head 17.3 15.6
The most troublesome pain site
Back/buttocks 27.9 32.6
Upper extremities 9.8 11.6
Lower extremities 15.8 14.1
Head/neck 5.8 4.2
Chest/abdomen/groin 3.3 2.4
More than 1 site 27.9 26.4
No site identified 9.1 8.4
Timing of pain
All the time and flare-ups 51.7 55.8
Single type of pain all the time 28.7 23.4
Single type of pain sometimes 19.6 20.9
Median (IQR) Median (IQR)
Neuropathic pain scale scores
Intensity 6.0 (5.0–8.0) 7.0 (5.0–8.0)
Sharp 7.0 (4.0–8.0) 7.0 (4.0–8.0)
Hot 4.0 (2.0–6.0) 3.0 (1.0–5.0)
Dull 5.0 (3.0–7.0) 5.0 (3.0–7.0)
Cold 0.0 (0.0–2.0) 0.0 (0.0–2.0)
Sensitive 3.0 (0.0–7.0) 1.0 (0.0–6.0)
Itchy 1.0 (0.0–5.0) 0.0 (0.0–4.0)
Unpleasant 6.0 (5.0–8.0) 6.0 (5.0–8.0)
Deep 7.0 (5.0–8.0) 7.0 (5.0–8.0)
Surface 5.0 (3.0–7.0) 4.0 (2.0–6.0)
Level of Expressed Need % %
Level 0 7.9 8.1
Level 1 9.1 10.0
Level 2 28.6 29.2
Level 3 14.7 12.4
Level 4 39.7 40.3
% %
Treatments or medications
Prescription opioids/anti-inflammatories 27.1 24.8
Over the counter analgesics 26.6 23.7
Nonmedication techniques 8.7 17.6
Combination therapy (medication and nonmedication) 7.9 7.0
Antiseizure or antidepressants 6.7 5.5
Others 13.0 11.3
None/missing response 10.0 10.2
aLikely or possible neuropathic pain diagnosis and ≥12 on the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs.
bLikely or possible neuropathic pain diagnosis and ≥3 on the Douleur Neuropathique 4.
cRespondents could choose more than one site.
10 Pain Research and Management
Table 4: Unadjusted and adjusted odds (95% CI) of likely or possible neuropathic pain using the S-LANSS and the DN4.
S-LANSSa DN4b
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Gender
Male 1.0 1.0 1.0 1.0
Female 1.39 (1.13–1.71) 1.46 (1.17–1.81) 0.67 (0.56–0.79) 0.60 (0.50–0.72)
Age
18–49 years 1.0 1.0 1.0 1.0
50–93 years 1.70 (1.38–2.10) 1.45 (1.13–1.85) 1.04 (0.87–1.23) 0.82 (0.67–1.02)
Marital status
Married or living as married 1.0 1.0 1.0 Removedc
Single, widowed, separated, or divorced 0.98 (0.79–1.23) 0.56 (0.44–0.72) 1.32 (1.11–1.58)
Education
High school or less 1.0 Removedc 1.0 Removedc
CEGEPd, trade or professional certificate, or others 0.96 (0.73–1.25) 0.70 (0.56–0.87)
Some university, degree, or graduate degree 0.57 (0.43–0.74) 0.43 (0.34–0.53)
Employment status
Working full- or part-time 1.0 1.0 1.0 1.0
Retired 1.60 (1.25–2.06) 0.65 (0.48–0.88) 1.43 (1.15–1.78) 1.09 (0.83–1.4)
Looking for, incapable of, or not looking for work 3.15 (2.46–4.03) 1.89 (1.43–2.46) 3.64 (2.97–4.47) 3.05 (2.42–3.84)
Income (Canadian)
≥$100,000 1.0 1.0 1.0 1.0
$50,000–$99,999 1.59 (1.15–2.21) 1.58 (1.13–2.21) 2.41 (1.85–3.13) 2.16 (1.65–2.83)
<$50,000 4.45 (3.31–5.97) 4.59 (3.26–6.46) 4.19 (3.25–5.41) 3.44 (2.59–4.58)
Smoking status
Never 1.0 1.0 1.0 1.0
Previous 2.23 (1.79–2.79) 1.86 (1.47–2.35) 2.07 (1.71–2.52) 1.69 (1.37–2.07)
Current 1.57 (1.16–2.13) 1.34 (0.97–1.85) 2.95 (2.35–3.70) 2.39 (1.88–3.05)
aLikely or possible neuropathic pain diagnosis and ≥12 on the Self-Report Leeds Assessment of Neuropathic Symptoms and Signs.
bLikely or possible neuropathic pain diagnosis and ≥3 on the Douleur Neuropathique en 4.
cVariables with 𝑝 < 0.10 removed using backward manual procedure.
dColle`ge d’Enseignement Ge´ne´ral et Professionnel (General and Vocational College).
considered them as having neuropathic pain, leading to an
overestimate of prevalence. Conversely, if respondents with a
true neuropathic pain diagnosis did not provide a pain diag-
nosis, despite having a positive score on the screening tools,
they would have been considered nonneuropathic, leading
to an underestimation of prevalence. Not all back problems
are neuropathic [55]; however we included all individuals
reporting a diagnosed back problem in our definition. Given
the high prevalence of back problems in our study (19.7%),
this may have resulted in an overestimate of prevalence of
neuropathic pain.When individualswith back problemswere
excluded, the prevalence of neuropathic pain dropped to
4.1% (S-LANSS) and 5.3% (DN4). We can also assess some
degree of underestimation. For example, of respondents who
reported chronic pain but did not provide a pain diagnosis,
18 were positive on the S-LANSS and 23 were positive on the
DN4. If all of these respondents had a true neuropathic pain
diagnosis, the prevalence would increase to 9.2% (S-LANSS)
and 13.4% (DN4).
The difference in prevalence of chronic pain with neuro-
pathic characteristics between the two screening toolsmay be
related to design and content of the questionnaires. Although
there are several specific neuropathic pain characteristics
common to both the S-LANSS and DN4, there are also dif-
ferences in these screening tools [56]. For example, “painful
cold,” “numbness,” and “itching” are included in the DN4
but not the S-LANSS, whereas “pain evoked by light touch”
and autonomic “colour changes” are only present in the S-
LANSS. In this study, median scores for the NPS items for
both “cold” and “itching” pain were zero; both of these pain
characteristics are included in DN4 but not in S-LANSS.
Future research is needed to explore the implications of
these differences. Five distinct subtypes of neuropathic pain
based on symptoms and sensory profiles have been identified,
alongside different frequencies in different neuropathic con-
ditions [57]. It is unclear whether these have implications for
management and response to treatment but as more evidence
emerges, subdividing the epidemiology of neuropathic pain
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may be explored [58]. Missing data may also explain the
discrepancy in prevalence. There was a higher proportion of
missing responses for the 7 items on the DN4 (9.2%–15.0%)
compared to the 7 items on the S-LANSS (2.0%–5.7%). This
may have been due to respondent fatigue given that the DN4
followed the S-LANSS in the order of the questions; however
the NPS followed the DN4 and the proportion of missing
responses for the NPS was lower than that for the DN4 and
similar to that of the S-LANSS. A more likely explanation
is the way in which the questions are posed on the DN4,
leading respondents to not answering when the response is
negative.
An important limitation of our study was the low
response rate which may have led to response bias, given
that individuals with chronic pain may be more likely to
respond to a survey about chronic pain [59]. The low
response rate was partially due to a postal strike, which may
have resulted in delayed delivery and lost questionnaires;
however this technical difficulty unlikely led to response
bias. A small proportion of respondents (8.5%) completed
online questionnaires, which may have had minimal effect
on the findings for the S-LANSS in particular, where a
higher proportion of respondents were positive for chronic
pain with neuropathic characteristics on paper versus online
questionnaires. However, respondents who completed paper
questionnaires were older and had lower income, factors also
associated with neuropathic pain. Therefore survey mode
was likely a confounder and thus was not included in
multivariable analyses. The low response rate in this study is
consistent with response rates for survey research, which are
declining in general [11, 60, 61], and although it may influence
our estimates of prevalence, it should have minimal effect on
risk factors associated with neuropathic pain.
This study provides evidence of a significant burden of
neuropathic pain in the general population of Canadians.
The highest burden was in males who were economically
disadvantaged. Prevalence varied by screening tool, indi-
cating more work is needed to develop reliable measures.
Better training of primary care practitioners and community
based clinical studies might help refine the precision of the
estimates. Given the major resource implications associated
with population level screening, screening could be targeted
towards groups known to be at increased risk for neuropathic
pain. Not only would this improve the sensitivity and speci-
ficity of screening, but also clinical examination to further
define the condition would be more manageable. Finally,
prospective studies are needed to shed more light on the
etiology and incidence of neuropathic pain.
Additional Points
This cross-sectional survey describes the epidemiology of
neuropathic pain in a community sample ofCanadians.Likely
or possible neuropathic pain was defined using a relevant
diagnosis and a positive screen on the Self-Report Leeds
Assessment of Neuropathic Symptoms and Signs (S-LANSS)
pain scale or the Douleur Neuropathique 4 (DN4)Questions.
Prevalence of likely neuropathic pain was 1.9% (S-LANSS)
and 3.4% (DN4). Prevalence of possible neuropathic pain was
5.8% (S-LANSS) and 8.1% (DN4). Males who were econom-
ically disadvantaged had the highest burden of neuropathic
pain. Prevalence varied by screening tool, indicating more
work is needed to develop reliable measures.
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